QGEN Allies to Grow in Cancer Research - Analyst Blog

By
A A A

Qiagen NV ( QGEN ) expanded its existing collaboration with Exosome Diagnostics for the development of a first-of-its-kind, non-invasive molecular in-vitro diagnostics that will help diagnose and monitor cancer patients. Qiagen will gain exclusive rights to market and sell the test globally. Financial details of the transaction, however, remain undisclosed.

The proposed test will use exosomes to detect certain mutations of an undisclosed gene associated with non-small cell lung cancer (NSCLC) and other tumors. Compared with current molecular diagnostics requiring tissue biopsy, the test will enable detection of cancer biomarkers in plasma and therefore, reduce both cost and patient risk.

The development of this technologically advanced test promises to improve cancer treatment methods. It will enable physicians to diagnose and monitor a patient's disease more comprehensively and in a time-effective manner. The test can be coupled with new anticancer therapeutics. The collaboration will see both companies combining their respective expertise to deliver advanced clinical research and healthcare standards by automating sample-to-result workflows and increasing cost efficiency and simplicity.

In a bid to strengthen its suite of diagnostic tests, Qiagen had announced a strategic partnership with Exosome on Jul 23, 2013. The deal was signed to develop an all inclusive range of biofluid nucleic acid kits. Qiagen has set a tentative target to launch the first set of products under this range in the second quarter of 2014.

Currently, Qiagen has a Zacks Rank #2 (Buy). Other better-ranked stocks in the broader healthcare sector include Actelion Ltd. ( ALIOF ), Affymetrix Inc. ( AFFX ) and Emergent BioSolutions, Inc. ( EBS ) . All these companies sport a Zacks Rank #1 (Strong Buy).



AFFYMETRIX INC (AFFX): Free Stock Analysis Report

ACTELION LTD (ALIOF): Get Free Report


EMERGENT BIOSOL (EBS): Free Stock Analysis Report

QIAGEN NV (QGEN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AFFX , ALIOF , EBS , QGEN

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

122,762,267
  • $15.81 ▼ 1.43%
62,277,320
  • $8.50 ▼ 6.80%
58,664,622
  • $128.46 ▼ 1.50%
48,473,163
  • $25.99 ▲ 0.39%
36,433,239
  • $5.12 ▲ 7.34%
35,593,669
  • $6.63 ▲ 5.41%
30,823,989
  • $16.68 ▼ 3.02%
30,676,302
    $2.08 unch
As of 2/27/2015, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com